Congrats Nanopath on this huge milestone! Great to see the impact you're beginning to make in women's health.
We're proud to announce that the FDA has granted Breakthrough Device Designation for our novel molecular diagnostic platform for complicated Urinary Tract Infections (cUTIs)! This designation is reserved by the FDA for devices that may offer more effective diagnosis or treatment of life-threatening or irreversibly debilitating conditions. This recognition validates the innovative nature of Nanopath's platform and its potential to significantly improve patient outcomes. This milestone will accelerate Nanopath's mission to transform care by bringing actionable molecular results— including pathogen identification and antibiotic resistance markers — to the point-of-care in 15 minutes, not days. Congratulations to the entire Nanopath team for this major achievement to further our vision of broadly accessible rapid molecular diagnostics! Learn more: https://lnkd.in/ey6nkYPZ Alison Burklund, Amogha Tadimety, Matthew Black, Matt Cote, Edward Evantash #FDA #BreakthroughDevice #Diagnostics #Biotech #MedTech
